Teck Confirms Receipt Of Revised Unsolicited Acquisition Proposal From Glencore

https://www.globenewswire.com/news-release/2023/04/11/2644632/0/en/Teck-Confirms-Receipt-of-Revised-Unsolicited-Acquisition-Proposal-from-Glencore.html Teck Resources Limited (TSX:TECK, NYSE:TECK) (“Teck”)

https://www.globenewswire.com/news-release/2023/04/11/2644632/0/en/Teck-Confirms-Receipt-of-Revised-Unsolicited-Acquisition-Proposal-from-Glencore.html

Teck Resources Limited (TSX:TECK, NYSE:TECK) (“Teck”) today confirmed that it has received a revised, unsolicited, non-binding proposal from Glencore plc, which would see that company acquire Teck.

Glencore’s revised proposal appears to be largely unchanged, with the exception of a cash consideration alternative in lieu of shares in the proposed combined coal entity. The revised proposal does not provide an increase in the overall value to be received by Teck shareholders or appear to address material risks previously raised by Teck.

Consistent with its fiduciary duties and in consultation with its financial and legal advisors, Teck’s Board of Directors (the “Board”) will carefully and expeditiously review and evaluate the new proposal. Teck will advise shareholders of the Board’s decision regarding the revised proposal as soon as practicable.

As previously announced on April 3, 2023, following a detailed review and assessment of a similar unsolicited proposal from Glencore, Teck’s Board unanimously determined that the proposal was not actionable and not in the best interests of Teck or its shareholders. The Board determined that the previously rejected Glencore proposal would have exposed Teck shareholders to material risks and uncertainty and would have transferred significant value to Glencore at the expense of Teck shareholders.

Advisors
Barclays Capital Canada Inc. and Ardea Partners LP are serving as financial advisors to Teck. Stikeman Elliott LLP and Paul, Weiss, Rifkind, Wharton & Garrison LLP are acting as legal advisors.

BMO Capital Markets, Goldman Sachs & Co. LLC, and Origin Merchant Partners are serving as financial advisors to the Special Committee and Blake, Cassels & Graydon LLP and Sullivan & Cromwell LLP are acting as legal advisors to the Special Committee.

Total
0
Shares
Related Posts
Read More

AstraZeneca to Present New Data Advancing Its Ambition to Redefine Care at the 2022 San Antonio Breast Cancer Symposium; Twelve Medicines and Potential New Medicines Will Be Featured in 55 Presentations

Data will show clinical opportunity in HR-positive advanced breast cancer for potential first-in-class AKT inhibitor capivasertib and next-generation oral SERD camizestrant. Enhertu data will reinforce potential to set new standards in HER2-targetable disease. Data for antibody drug conjugate datopotamab deruxtecan will demonstrate potential in HR-positive and triple-negative breast cancer.

AZN

Read More

Disc Medicine Announces Planned Departure Of Chief Financial Officer Joanne Bryce; Co Initiated A Search To Fill The Position. Ms. Bryce Plans To Remain With The Co And Oversee Her Current Responsibilities Until A Successor Has Been Identified

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases,

IRON